

Running the Numbers

*A Periodic Feature to Inform North Carolina Health Care Professionals
About Current Topics in Health Statistics*

Behavioral Health Trends Among Perinatal North Carolina Medicaid Beneficiaries

Untreated behavioral health conditions among the perinatal population are associated with high mortality and morbidity. We examined trends of behavioral health conditions and treatment received by perinatal Medicaid beneficiaries and described the characteristics of providers treating these beneficiaries from 2017 to 2022. Results indicated that 24.4% of beneficiaries had a behavioral health diagnosis, 13.8% received a psychotropic prescription, and 7.1% received a behavioral health service.

Introduction

Maternal behavioral health during the perinatal period, defined as conception through the first year following birth, affects not only maternal health and well-being but also the developing fetus, birth outcomes, and the child's development [1]. Approximately 20% of women experience behavioral health concerns during the perinatal period, and 38% report behavioral health as a top postpartum (i.e., first year following birth) complication [2, 3]. The societal cost of untreated perinatal mood and anxiety disorders is approximately \$14 billion [4]. Suicide and overdose/poisoning related to substance use are the leading underlying causes of maternal death, accounting for nearly 32% of deaths amid this population in North Carolina and 20% to 23% of deaths nationally [5, 6].

Despite the high burden of mortality and morbidity of maternal behavioral health conditions, many women do not receive behavioral health treatment, especially during pregnancy. Prior research has illustrated that 75% to 80% of pregnant women experiencing depressive symptoms receive inadequate treatment or no treatment at all [7-9]. Additionally, pregnant women with depression are significantly less likely to receive treatment than non-pregnant women with depression [10]. Some providers are reluctant to prescribe

depression medication to pregnant women due to their lack of knowledge about the safety of depression medication use during pregnancy and fears about malpractice risks [11].

Although there has been a longstanding behavioral health crisis, the COVID-19 pandemic exacerbated this concern and increased isolation and loneliness [12]. Perinatal women are a vulnerable population due to the stressors of pregnancy and new parenthood, as well as high—often preventable—rates of maternal death. Given the growing concern about perinatal behavioral health, our study aimed 1) to describe the prevalence of behavioral health diagnoses and treatment received by perinatal NC Medicaid enrollees, and 2) describe the characteristics of providers treating perinatal beneficiaries.

Methods

NC Medicaid institutional, professional, pharmacy, enrollment, and provider data from January 1, 2017, through September 30, 2023, provided by the North Carolina Department of Health and Human Services (NCDHHS) were analyzed. Perinatal Medicaid beneficiaries were included in our study if they met the following criteria: 1) pregnant at any point during the study period [13], 2) completed pregnancy (e.g., delivery, stillbirth, miscarriage, termination) or last pregnancy care visit on or before December 31, 2022, and 3) for pregnancies with unknown outcomes, must have two or more pregnancy care visits/services 30 to 183 days

Electronically published September 9, 2024.

Address correspondence to Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences, 2608 Erwin Rd, Suite 300, Durham, NC 27705 (alexis.french@duke.edu).

N C Med J. 2024;85(5):322-328. ©2024 by the North Carolina Institute of Medicine and The Duke Endowment. All rights reserved. 0029-2559/2024/85512

apart [13]. We excluded perinatal Medicaid beneficiaries who were dually enrolled in Medicare at any point during the perinatal period (i.e., pregnancy through the first 60 days following the pregnancy outcome or last prenatal care visit date). Providers were included if they were on a claim for an outcome (prescribing, behavioral health service) for at least one patient in the patient study cohort during that patient's perinatal period.

Patient behavioral health variables were assessed during the perinatal period. The pregnancy period was calculated using the pregnancy outcome date (e.g., live birth, miscarriage) minus the calculated gestational age [13]. For beneficiaries with unknown outcome, we limited their pregnancy period to the first and last dates of prenatal care [13]. Behavioral health diagnoses were defined as having at least one claim with a qualifying ICD-10-CM behavioral health diagnosis. Behavioral health services, which included psychiatric evaluation, psychotherapy, and intensive behavioral health services, were identified based on CPT, revenue, and categories of service codes. The total number of services was summed per person and dichotomized as any (≥ 1) versus none (0) for each behavioral health service type and overall behavioral health services. Filled psychotropic prescriptions by drug class were assessed based on the prescription claim fill date. Each drug class was defined as having at least one fill with one of the generic names (any versus none). Providers were identified on the claim for that outcome. If a provider had more than one specialty, the more relevant specialty was selected.

We determined the prevalence of each behavioral health diagnosis, behavioral health service use, and psychotropic medication use by calculating the number of pregnancies that meet those criteria out of total number of pregnancies. Overall rates were calculated using each person's first pregnancy in the study period. Yearly rates were calculated using each person's first pregnancy in that year, allowing beneficiaries to contribute multiple pregnancies during the study period. Descriptive statistics were calculated overall and by year for patient characteristics, behavioral health diagnoses, behavioral health treatment, and overall for provider specialty type. NCDHHS and Duke University Institutional Review Board approved this study.

Results

Of the 327,155 unique NC Medicaid beneficiaries who were pregnant during 2017–2022, 58.9% were White, 32.5% were Black/African American, 5.1% were multiracial, 3.3% were some other race, and for 0.1% race was unknown (Supplemental Table 1). A majority of pregnant beneficiaries were non-Hispanic (77.2%) and resided in an urban area (73.2%). The median age was 26.0 years, and most beneficiaries were eligible for Medicaid due to pregnancy (35.3%) or income (37.3%).

SUPPLEMENTAL TABLE 1 Patient Characteristics of the Perinatal Cohort Who Have Outcomes in 2017–2022

This appendix is available in its entirety in the online edition of the NCMJ.


Behavioral Health Diagnoses

Approximately one-quarter of the beneficiaries had a behavioral health diagnosis during 2017–2022 (Supplemental Table 2). The most common diagnoses were anxiety and obsessive-compulsive disorders (12.2%), depressive disorders (11.5%), substance use disorders (6.8%), bipolar and mood-related disorders (3.0%), post-traumatic stress disorder (PTSD) and other trauma-related disorders (2.6%), and attention-deficit/hyperactivity disorder (ADHD) (2.0%). The percentage of beneficiaries with any behavioral health diagnosis increased from 2017 (23.1%) to 2022 (26.8%), with the highest rate in 2021 (28.0%). The rate of anxiety and obsessive-compulsive disorders increased from 10.5% in 2017 to 15.8% in 2022 (Figure 1). PTSD and other trauma-related disorders increased slightly from 2017 (2.2%) to 2022 (3.4%). Similarly, the rate of ADHD increased

SUPPLEMENTAL TABLE 2 Patient Behavioral Health Characteristics During the Perinatal Period, Among Those With Pregnancy Outcomes in 2017–2022

This appendix is available in its entirety in the online edition of the NCMJ.

FIGURE 1.
Behavioral Health Diagnoses in North Carolina, 2017-2022



during the six years from 1.8% in 2017 to 2.4% in 2022. The percentage of beneficiaries with depressive disorders increased from 2017 (10.6%) to 2021 (14.1%) followed by a sharp decline in 2022 (9.8%). The percentage of beneficiaries with a substance use disorder rose from 7.3% in 2017 to 8.2% in 2019 and then decreased to 6.6% in 2022. The rate of bipolar disorders remained stable from 2017 (3.1%) to 2022 (3.3%).


Behavioral Health Treatment

Between 2017 and 2022, 13.8% of perinatal beneficiaries filled at least one psychotropic prescription and 7.1% received at least one behavioral health service (Supplemental Table 2). The most common psychotropic prescriptions were antidepressants (9.1%), sedating antihistamines (2.7%), benzo-analog and other insomnia medications (2.1%), benzodiazepines (1.7%), antipsychotics (1.4%), addiction medications (1.3%), mood stabilizers (0.9%), and stimulants (0.8%). Overall, 7.1% of beneficiaries received a behavioral health service during their perinatal period; 4.6% received psychotherapy, 4.5% received an initial diagnostic

evaluation, and 1.5% received intensive behavioral health services (e.g., residential substance use treatment program, halfway house).

The percentage of perinatal beneficiaries receiving any psychotropic prescription was about 16% between 2017 and 2020, before decreasing to 13.8% in 2021 and then 8.0% in 2022. The largest decline was among antidepressant prescriptions (Figure 2), with a decrease from 10.5% in 2017 to 3.0% in 2022. Prescriptions for benzodiazepines and addiction medications also declined from 2017 (2.5% and 1.5%, respectively) to 2022 (1.5% and 0.8%, respectively). The percentage of stimulant prescriptions remained stable during the study period. Among those who received any behavioral service, the percentage slightly increased from 2017 (7.3%) to 2022 (7.9%). A larger percentage of beneficiaries received psychotherapy in 2022 (5.2%) compared to in 2017 (4.7%) (Figure 2). A decrease in intensive behavioral health services was seen during the study period with 1.7% receiving this service in 2017 compared to 1.3% in 2022. The rate of initial diagnostic evaluations remained stable from 2017 to 2022.

FIGURE 2.
Behavioral Health Treatment in North Carolina,
2017-2022



Note. In pane A, the figure represents the percentage of beneficiaries who received at least one psychotropic prescription fill by drug class. Beneficiaries may be counted in more than one drug class and/or year. In pane B, the figure represents the percentage of beneficiaries who received at least one behavioral health service. Beneficiaries may be counted in more than one behavioral health service category and/or year.

Provider Specialty

During 2017-2022, 14,036 unique providers prescribed a psychotropic medication to these beneficiaries (Supplemental Table 3). Among the prescribers, one-third were nurse practitio-

ners (21.1%) and physician assistants (15.6%) (Figure 3). Other prescribing providers included family medicine (16.9%), obstetrics and gynecology (10.4%), internal medicine (7.3%), midwives (2.3%), pediatricians (2.0%), and other physicians (11.3%). Psychiatry providers (i.e., psychiatrists) only accounted for 7.5% of all unique prescribers. For behavioral health services, perinatal Medicaid beneficiaries received treatment from 8,379 unique providers (Supplemental Table 3).

Discussion


This study examined trends of behavioral health diagnosis and treatment among perinatal Medicaid beneficiaries in North Carolina from 2017 through 2022. Results indicated that about 1 in 4 beneficiaries had a behavioral health diagnosis, similar to findings by Fawcett and colleagues [2]. The rate of behavioral health diagnoses may be under-identified given that 13% to 20% of women are not screened for depression during pregnancy or postpartum [7]. The overall rate of diagnosis increased from 2017 to 2022, which reflects a worsening of behavioral health symptoms that may be associated with the COVID-19 pandemic, consistent with prior findings [14].

While there was an increase in the overall rate of diagnoses from 2017 to 2022, there was a decrease in the percentage of beneficiaries with a depressive disorder, which dropped to below the pre-pandemic rate in 2022. The decrease in depressive disorders in 2022 is in contrast to the slight increase in anxiety and obsessive-compulsive disorders from 2021 to 2022. Although we did not have access to screening rates for this analysis, it is possible fewer women were screened for behavioral health concerns—specifically depression—during this year compared to prior years. One study found that those with a telehealth visit who were enrolled in Medicaid were less likely to have a depression screening completed during the COVID-19 pandemic compared to those with an in-person visit and private insurance [15]. Many national organizations have recommended behavioral health screening during the first and second half of pregnancy and during the postpartum period, but there is a lack of consensus regarding frequency, timing, and process related to screening [16-20].

SUPPLEMENTAL TABLE 3 Provider Taxonomies of Those Who Provided Behavioral Health Treatment to a Pregnant Medicaid Beneficiary in the Perinatal Period

This appendix is available in its entirety in the online edition of the *NCMJ*.

FIGURE 3.
North Carolina Prescriber Provider Specialty



A greater proportion of beneficiaries received psychotropic prescriptions than behavioral health services, which is likely due to the limited availability of psychotherapy providers and other social drivers of health. National organizations recommend the use of medications to treat perinatal depression and anxiety, but many times patients and providers have concerns about the potential risks to the fetus [21, 22]. Providers treating perinatal patients often do not receive sufficient training on management of behavioral health conditions [23]. We found that approximately 37% of unique providers prescribing psychiatric medications to perinatal beneficiaries were nurse practitioners and physician assistants, suggesting limited behavioral health training. Our study found that antidepressants were the most common psychotropic medication prescribed to perinatal patients overall, but there was a stark decline in these prescriptions from 2020 to 2022, which is likely related to the decrease in the rate of depressive disorders in 2022. Other factors that may have influenced the rate of antidepressants include patient preference, limited access to prescribing providers, and lack of provider comfort and knowledge.

Perinatal psychiatry access programs can help address the behavioral health needs of perinatal women. NC MATTERS (Making Access to Treatment, Evaluation, Resources, and Screening Better) is a state and federally funded program that offers provider-to-provider consultation and education regarding assessment, diagnosis, and treatment of perinatal behavioral health conditions in North Carolina. This program aims to increase the capacity of health care providers to manage behavioral health conditions among perinatal patients [24]. As the NC MATTERS program continues to expand over time, the number of providers treating perinatal beneficiaries will likely increase and result in more perinatal women getting the behavioral health care that they need, including diagnosis and prescriptions.

Our study had several limitations. First, our sample was limited to beneficiaries with continuous Medicaid coverage during the perinatal period and thus our findings may not be generalizable to other populations. Additionally, since we only examined behavioral health diagnoses and treatment at conception through the first 60 days following birth, we did not know if beneficiaries received behavioral

health treatment later in the postpartum period. Given the nature of claims data, we were unable to assess the validity of diagnoses, the rate of screening, and the timing of the diagnosis in relation to the receipt of treatment.

While behavioral health conditions are common among perinatal women, there are barriers to accessing care for these conditions. Future research should aim to better understand how to increase early detection and improve diagnosis and treatment of perinatal behavioral health conditions as well as how policies and initiatives may impact access to care and behavioral health outcomes, such as Medicaid coverage extension through 12 months postpartum, expansion of and increased capacity of the perinatal behavioral health workforce, and increased access to care. Furthermore, it will be important to also examine the role of health disparities in perinatal behavioral health care and identify strategies for addressing structural inequities. **NCMJ**

Alexis French, PhD Assistant Professor, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina.

Kelley A. Jones, PhD, MPH Senior Biostatistician, Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina.

Naomi O. Davis, PhD Assistant Professor, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina.

Karen Burns, MSW, LCSW-A Research Instructor, Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.

Tara Owens Shuler, M.Ed., LCCE, CD (DONA) Branch Head, Maternal Health Branch - Women, Infant, and Community Wellness Section, Division of Public Health - North Carolina Department of Health and Human Services, Raleigh, North Carolina.

Andi Davis, BA Research Assistant, Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.

Gary Maslow, MD Associate Professor of Psychiatry and Behavioral Sciences and Assistant Professor of Pediatrics, Duke University School of Medicine, Durham, North Carolina.

Mary Kimmel, MD, PhD Assistant Professor, Department of Psychiatry, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina.

Acknowledgments

Disclosure of interests. Dr. Gary Maslow receives grant support from Substance Abuse Mental Health Services Administration (SAMHSA), NC Medicaid, North Carolina Department of Health and Human Services, and Healthy Blue and has received research funding from Pfizer, the National Institutes of Health, and the Arc of North Carolina.

Dr. Mary Kimmel was a PI on an investigator-led study with Sage Therapeutics, which ended over a year ago. Her spouse has some stock in Abbvie.

References

1. Ahmad M, Vismara L. The psychological impact of COVID-19 pandemic on women's mental health during pregnancy: a rapid evidence review. *Int J Environ Res Public Health*. 2021;18(13):7112. doi: 10.3390/ijerph18137112
2. Fawcett EJ, Fairbrother N, Cox ML, White IR, Fawcett JM. The prevalence of anxiety disorders during pregnancy and the postpartum period: a multivariate Bayesian meta-analysis. *J Clin Psychiatry*. 2019;80(4):18r12527. doi:10.4088/JCP18r12527
3. *From Pregnancy to Policy: The Experiences of Birthing People in the United States*. AAMC Center for Health Justice. Accessed on June 4, 2024. <https://www.aamchealthjustice.org/media/3391/download?attachment>
4. Luca DL, Margiotta C, Staatz C, Garlow E, Christensen A, Zivin K. Financial toll of untreated perinatal mood and anxiety disorders among 2017 births in the United States. *Am J Public Health*. 2020;110(6):888-896. doi: 10.2105/AJPH.2020.305619
5. CDC. Pregnancy-Related Deaths: Data From Maternal Mortality Review Committees in 36 U.S. States, 2017-2019. 2024. Accessed June 4, 2024. https://www.cdc.gov/maternal-mortality/php/data-research/mmrc-2017-2019.html?CDC_AAref_Val=https://www.cdc.gov/reproductivehealth/maternal-mortality/erase-mm/data-mmrc.html
6. *2018-2019 Maternal Mortality Review Report*. North Carolina Department of Health and Human Services. 2024. Accessed on June 4, 2024. <https://wicws.dph.ncdhhs.gov/docs/MMRCReport.pdf>
7. Identifying Maternal Depression. CDC. 2020. Accessed on June 4, 2024. https://archive.cdc.gov/www_cdc_gov/reproductivehealth/vital-signs/identifying-maternal-depression/VS-May-2020-Maternal-Depression_h.pdf
8. Clarke DE, De Faria L, Alpert JE, The Perinatal Mental Health Advisory Panel, The Perinatal Mental Health Research Team. *Perinatal Mental and Substance Use Disorder: White Paper*. Washington, DC: American Psychiatric Association. 2023. Accessed on June 4, 2024. <https://www.psychiatry.org/getmedia/344c26e2-cdf5-47dfa5d7-a2d444fc1923/APA-CDC-Perinatal-Mental-and-Substance-Use-Disorders-Whitepaper.pdf>
9. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The perinatal depression treatment cascade: baby steps toward improving outcomes. *J Clin Psychiatry*. 2016;77(9):1189-1200. doi:10.4088/JCP15r10174
10. Sanmartin MX, Ali MM, Chen J, Dwyer DS. Mental health treatment and unmet mental health care need among pregnant women with major depressive episode in the United States. *Psychiatr Serv*. 2019;70(6):503-506. <https://doi.org/10.1176/appi.ps.201800433>
11. Weinreb L, Byatt N, Moore Simas TA, Tenner K, Savageau JA. What happens to mental health treatment during pregnancy? Women's experience with prescribing providers. *Psychiatr Q*. 2014;85(3):349-355. doi:10.1007/s1126-014-9293-7
12. *Our Epidemic of Loneliness and Isolation: The U.S. Surgeon General's Advisory on the Healing Effects of Social Connection and Community*. Office of the Surgeon General (OSG). Washington (DC): US Department of Health and Human Services; 2023. Accessed on June 10, 2024. https://www.ncbi.nlm.nih.gov/books/NBK595227/pdf/Bookshelf_NBK595227.pdf
13. Sarayani A, Wang X, Thai TN, Albogami Y, Jeon N, Winterstein AG. Impact of the transition from ICD-9-CM to ICD-10-CM on the identification of pregnancy epi-

- sodes in US health insurance claims data. *Clin Epidemiol.* 2020;12:1129-1138. doi: 10.2147/CLEP.S269400
14. Iyengar U, Jaiprakash B, Haitzuka H, Kim S. One year into the pandemic: a systematic review of perinatal mental health outcomes during COVID-19. *Front Psychiatry.* 2021;12:674194. doi:10.3389/fpsy.2021.674194
 15. Garcia ME, Neuhaus J, Livaudais-Toman J, et al. Telemedicine and depression screening after the start of the COVID-19 pandemic. *JAMA Netw Open.* 2024;7(2):e2355830. doi: 10.1001/jamanetworkopen.2023.55830
 16. Screening and Diagnosis of Mental Health Conditions During Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 4. *Obstet Gynecol.* 2023;141(6):1232-1261. doi: 10.1097/AOG.00000000000005200
 17. *Position Statement on Screening and Treatment of Mood and Anxiety Disorders During Pregnancy and Postpartum.* American Psychological Association. Accessed on June 4, 2024. <https://www.psychiatry.org/file%20library/about-apa/organization-documents-policies/policies/positions-screening-and-treatment-mood-anxiety-disorders-during-pregnancy-postpartum.pdf>
 18. Earls MF, Yogman MW, Mattson G, et al. Incorporating recognition and management of perinatal depression into pediatric practice. *Pediatrics.* 2019;143(1):e20183259. doi: 10.1542/peds.2018-3259
 19. Siu AL, Bibbins-Domingo K, Grossman DC, et al.; US Preventive Services Task Force (USPSTF). Screening for depression in adults: US preventive services task force recommendation statement. *JAMA.* 2016;315(4):380. doi: 10.1001/jama.2015.18392
 20. Ayala NK, Lewkowitz AK, Whelan AR, Miller ES. Perinatal mental health disorders: a review of lessons learned from obstetric care settings. *Neuropsychiatr Dis Treat.* 2023;19:427-432. doi: 10.2147/NDT.S292734
 21. Creeley CE, Denton LK. Use of prescribed psychotropics during pregnancy: a systematic review of pregnancy, neonatal, and childhood outcomes. *Brain Sci.* 2019;9(9):235. doi: 10.3390/brainsci9090235
 22. Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5. *Obstet Gynecol.* 2023;141(6):1262-1288. doi: 10.1097/AOG.00000000000005202
 23. Garbarino AH, Kohn JR, Coverdale JH, Kilpatrick CC. Current trends in psychiatric education among obstetrics and gynecology residency programs. *Acad Psychiatry J Am Assoc Dir Psychiatr Resid Train Assoc Acad Psychiatry.* 2019;43(3):294-299. doi: 10.1007/s40596-019-01018-w.
 24. Kimmel M. Maternal Mental Health MATTERS. *N C Med J.* 2020;81(1):45-50. doi: 10.18043/ncm.81.1.45

SUPPLEMENTAL TABLE 1.
Patient Characteristics of the Perinatal Cohort
Who Have Outcomes in 2017–2022

Variable	Overall
N	327,155
Patient characteristics	
Age, years, Median (Q1, Q3)	26.0 (22.0, 31.0)
Age group	
<18 years	9,966 (3.0%)
18–24 years	118,581 (36.2%)
25–29 years	93,387 (28.5%)
30–34 years	63,649 (19.5%)
35–39 years	32,285 (9.9%)
40+ years	9,287 (2.8%)
Race	
Black/African American	106,479 (32.5%)
White	192,541 (58.9%)
Other race	10,895 (3.3%)
Multiracial	16,751 (5.1%)
Unknown	489 (0.1%)
Hispanic/Latino ethnicity	
Non-Hispanic	252,678 (77.2%)
Hispanic	73,391 (22.4%)
Unreported	1,086 (0.3%)
Urban/rural status	
Rural	77,120 (23.6%)
Urban	239,570 (73.2%)
Unreported	10,465 (3.2%)
Medicaid eligibility on outcome date	
Medicaid for Pregnant Women	115,631 (35.3%)
Income-eligible adult	122,033 (37.3%)
Pediatric programs	39,092 (11.9%)
Other	50,399 (15.4%)

Note. Each unique beneficiary represented once per column for years in which they have outcomes.

SUPPLEMENTAL TABLE 2.
Patient Behavioral Health Characteristics During the Perinatal Period,
Among Those with Pregnancy Outcomes in 2017-2022

Variable	Overall
N	327,155
Behavioral health diagnoses	
Any behavioral health disorder	79,851 (24.4%)
Attention-deficit/hyperactivity disorder	6,385 (2.0%)
Depressive disorders	37,566 (11.5%)
Postpartum depression	4,653 (1.4%)
Postpartum psychosis and mood disturbance	875 (0.3%)
Anxiety and obsessive-compulsive disorders	39,972 (12.2%)
Bipolar and mood-related disorders	9,783 (3.0%)
Schizophrenia and related disorders	2,056 (0.6%)
Adjustment disorder	5,983 (1.8%)
Disruptive, impulse-control, and conduct disorders	1,145 (0.3%)
Post-traumatic stress disorder and other trauma-related disorders	8,447 (2.6%)
Disruptive mood dysregulation disorder	262 (0.1%)
Autism spectrum disorder	227 (0.1%)
Substance use disorders	22,195 (6.8%)
Intellectual disability	327 (0.1%)
Neurodevelopmental disability	146 (0.0%)
Somatic symptom disorders	561 (0.2%)
Eating and feeding disorders	998 (0.3%)
Gender dysphoria	14 (0.0%)
Personality disorders	1,576 (0.5%)
Psychotropic medication fills	
Any psychotropic prescription fill	45,244 (13.8%)
Antidepressant	29,628 (9.1%)
Tricyclic antidepressant	711 (0.2%)
Mood stabilizer	2,984 (0.9%)
Antipsychotic	4,450 (1.4%)
Stimulant	2,529 (0.8%)
Non-stimulant ADHD medication	143 (0.0%)
Addiction medication	4,380 (1.3%)
Benzodiazepine	5,616 (1.7%)
Alpha agonist	1,083 (0.3%)
Sedating antihistamine	8,966 (2.7%)
Benzo-analog and other insomnia medication	6,981 (2.1%)
Behavioral health services	
Any behavioral health service	23,099 (7.1%)
Diagnostic evaluation or psychotherapy	21,505 (6.6%)
Initial diagnostic evaluation	14,652 (4.5%)
Psychotherapy	15,034 (4.6%)
Intensive behavioral health services	4,927 (1.5%)

SUPPLEMENTAL TABLE 3.**Provider Taxonomies of Those Who Provided Behavioral Health Treatment to a Pregnant Medicaid Beneficiary in the Perinatal Period**

Variable	Psychotropic medication prescribers	Behavioral health service provider
Number of providers	14,036	8,379
Provider taxonomy category		
Psychologist	0 (0%)	369 (4.4%)
Social worker	2 (0.0%)	2,840 (33.9%)
Counselor	2 (0.0%)	3,578 (42.7%)
Psychiatry	1,053 (7.5%)	524 (6.3%)
Physician Assistant	2,189 (15.6%)	116 (1.4%)
Nurse Practitioner	2,965 (21.1%)	276 (3.3%)
Internal Medicine	1,020 (7.3%)	27 (0.3%)
Family Medicine	2,377 (16.9%)	21 (0.3%)
Midwives	320 (2.3%)	18 (0.2%)
Obstetrics & Gynecology	1,454 (10.4%)	61 (0.7%)
Pediatrics	284 (2.0%)	11 (0.1%)
Other physicians	1,592 (11.3%)	159 (1.9%)
Other non-physicians	769 (5.5%)	62 (0.7%)
Agencies/Facilities/Suppliers	9 (0.1%)	317 (3.8%)

Note. Providers are shown in one taxonomy category each. Services and prescriptions must have been provided during the perinatal period (last menstrual period through 60 days postpartum). There were several providers who prescribed medications but were behavioral health service providers only (social worker, counselor). We elected to retain them in the psychotropic medication prescribers for completeness.